Receptor Pharmacology in Research Contexts Non-clinical characterization published by third parties describes uneven activity across the three targets, with reported potency at the GIP receptor exceeding that observed at the glucagon and GLP-1 receptors when measured against their endogenous ligands
So with all of these, there are indications, contraindications, and a risk-benefit profile that you have to talk about with patients
Clinical evidence indicates substantial decreases in hepatic fat accumulation before the onset of severe illness, with studies documenting alanine transaminase (ALT) normalisation in 40% of individuals exhibiting baseline increases (Buse et al
27 It is well known that enteroendocrine cells produce low basal levels of GLP-1 during pre-prandial state, however after food ingestion the synthesis and secretion of GLP-1 sharply raises with a peak 3060 min following nutrient intake
licensed UK alternatives such as semaglutide (Wegovy) and tirzepatide (Mounjaro) are available through NICE-aligned prescribing pathways
GLP-1